Damora Therapeutics (DMRA) Non Operating Investment Income (2021 - 2024)
Damora Therapeutics posted quarterly Non Operating Investment Income of $2000.0 for Q2 2024, down 92.0% year-on-year from $25000.0 in Q3 2023, and down 93.75% on a QoQ basis from $32000.0 in Q1 2024.
Damora Therapeutics (DMRA) has 4 years of Non Operating Investment Income data on file, last reported at $2000.0 in Q2 2024.
- For the quarter ending Q2 2024, Non Operating Investment Income fell 92.0% year-over-year to $2000.0; the trailing twelve-month figure through Sep 2024 stood at $92000.0 (down 74.16% YoY), and the FY2023 full-year result was $231000.0, up 189.19% from the prior year.
- Non Operating Investment Income for Q2 2024 stood at $2000.0, down from $32000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $183000.0 in Q4 2022 and bottomed at -$205000.0 in Q1 2022.
- The 4-year median for Non Operating Investment Income is $24000.0 (2021), against an average of -$5071.4.
- Peak annual rise in Non Operating Investment Income reached 438.89% in 2022, while the deepest fall reached 773.91% in 2022.
- A 4-year view of Non Operating Investment Income shows it stood at -$54000.0 in 2021, then jumped by 438.89% to $183000.0 in 2022, then tumbled by 68.31% to $58000.0 in 2023, then sank by 96.55% to $2000.0 in 2024.
- The last three Non Operating Investment Income figures came in at $2000.0 (Q2 2024), $32000.0 (Q1 2024), and $58000.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Dec 31, 2023 | 58,000.00 |
| Sep 30, 2023 | 56,000.00 |
| Sep 30, 2023 | 56,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Mar 31, 2023 | 92,000.00 |
| Mar 31, 2023 | 92,000.00 |
| Dec 31, 2022 | 183,000.00 |
| Dec 31, 2022 | 183,000.00 |
| Sep 30, 2022 | -82,000.00 |
| Sep 30, 2022 | -82,000.00 |
| Jun 30, 2022 | -155,000.00 |
| Jun 30, 2022 | -155,000.00 |
| Mar 31, 2022 | -205,000.00 |
| Mar 31, 2022 | -205,000.00 |
| Dec 31, 2021 | -54,000.00 |
| Dec 31, 2021 | -54,000.00 |
| Sep 30, 2021 | 34,000.00 |
| Sep 30, 2021 | 34,000.00 |
| Jun 30, 2021 | 23,000.00 |
| Jun 30, 2021 | 23,000.00 |
| Mar 31, 2021 | -80,000.00 |
| Mar 31, 2021 | -80,000.00 |